Premium
Gemcitabine in the treatment of relapsed lymphomas
Author(s) -
Boulos Badi M.,
Jajeh Ahmad,
Tamkus Drimante,
Menini Perry
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.1135.1
Subject(s) - gemcitabine , medicine , lymphoma , mycosis fungoides , mantle cell lymphoma , oncology , deoxycytidine , chemotherapy , refractory (planetary science) , cancer research , gastroenterology , biology , astrobiology
Gemcitabine is a diflourinated analyogue of deoxycytidine. It acts as an anti metabilile. It is cell cycle specific and block cell in G 1 /s interface. It is phosphorylated to its active form and is excreted slowly than other chemotherapeutic drugs. It inhibits DNA synthesis via depletion of cellular deoxynucleotide pools and by way of masked DNA chain termination. A total of 54 patients were treated and have been followed for seven years. Mean age was 54 years. There were 42 males and 12 females. There were 12 Hispanic, 15 White, 24 African American and 3 others. Mycosis fungoides reversal stage (4), Mantle cell NHL (non‐hodgkins lymphoma) (2), Peripheral T‐Cell NHL including NK (natural killer), cell Gamma/Delta sub‐type Lymphoma (7), Anaplastic New cell NHL (2), composite NHL (1), NHL (23), HD (10), other cell sLL/Richter Transformation (5). The response rate was over 75% achieved in patients with NHL with advanced stages III & IV. None of the patients had grade 3 or 4 toxicity. In conclusion gemcitabine is a valid and safe option in the treatment of relapsed and refractory cases of lymphomas.